The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Concurrent Cisplatin, Etoposide, and Chest Radiotherapy in Pathologic Stage IIIB Non–Small-Cell Lung Cancer: A Southwest Oncology Group Phase II Study, SWOG 9019
Abstract
PURPOSE: There are no published survival data after chemoradiotherapy (chemoRT) in pathologically documented stage IIIB non–small-cell lung cancer. Studies of radiotherapy (RT) alone or chemotherapy followed by RT yield 5-year survivals less than 10%. The Southwest Oncology Group (SWOG) employed the same concurrent chemoRT induction regimen used in its predecessor trimodality trial to determine the efficacy, safety, and long-term outcome of replacing postinduction surgery with additional chemoRT. PATIENTS AND METHODS: Eligible patients for SWOG-9019 had pathologic documentation of T4N0/1, T4N2, or N3 stage IIIB non–small-cell lung cancer. They had pulmonary function adequate to withstand combined-modality therapy, identical to the requirements of the previous trial with postchemoRT surgery. Induction therapy was two cycles of cisplatin plus etoposide (PE) concurrent with once-daily thoracic RT (45 Gy). In the absence of progressive disease, RT was completed to 61 Gy, with two additional cycles of cisplatin plus etoposide. RESULTS: Fifty eligible patients were accrued with tumor-node (TN) substage confirmed on central review: 18, T4N0/1; 12, T4N2; and 20, N3. Grade 4 neutropenia was the most common toxicity (32%). Grade 3/4 esophagitis occurred in 12% and 8%. Median follow-up was 52 months, and overall median survival was 15 months (10 to 22, 95% confidence interval). Three- and 5-year survivals were 17% and 15% (5-year T4N0/1, 17%; T4N2, 13%; and N3, 15%). CONCLUSION: Feasibility and long-term survival support the application of these results as a standard against which mature outcomes of chemoRT trials with new chemotherapy agents can be compared. These results also justify use of the SWOG-9019 approach as a control arm in ongoing phase III trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Furuse, K., Fukuoka, M., Kawahara, M., Nishikawa, H., Takada, Y., Kudoh, S., Katagami, N., & Ariyoshi, Y. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2692 · Cited by 1,495
Effects of Concomitant Cisplatin and Radiotherapy on Inoperable Non-Small-Cell Lung Cancer
Schaake-Koning, C., van den Bogaert, W., Dalesio, O., Festen, J., Hoogenhout, J., van Houtte, P., Kirkpatrick, A., Koolen, M., Maat, B., Nijs, A., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202203260805 · Cited by 1,277
Dillman, R. O., Herndon, J., Seagren, S. L., Eaton, W. L., & Green, M. R. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.17.1210 · Cited by 923
Albain, K. S., Rusch, V. W., Crowley, J. J., Rice, T. W., Turrisi, A. T., Weick, J. K., Lonchyna, V. A., Presant, C. A., McKenna, R. J., & Gandara, D. R. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.8.1880 · Cited by 856
Self-citationEberhardt, W., Wilke, H., Stamatis, G., Stuschke, M., Harstrick, A., Menker, H., Krause, B., Müeller, M. R., Stahl, M., Flasshove, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.622 · Cited by 328
Choy, H., Akerley, W., Safran, H., Graziano, S., Chung, C., Williams, T., Cole, B., & Kennedy, T. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3316 · Cited by 235
Cited by
Aupérin, A., Le Péchoux, C., Rolland, E., Curran, W. J., Furuse, K., Fournel, P., Belderbos, J., Clamon, G., Ulutin, H. C., Paulus, R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2543 · Cited by 1,878
Albain, K. S., Swann, R. S., Rusch, V. W., Turrisi, A. T., Shepherd, F. A., Smith, C., Chen, Y., Livingston, R. B., Feins, R. H., Gandara, D. R., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60737-6 · Cited by 1,470
Self-citation_, _. (2008) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2008.0021 · Cited by 735
Ettinger, D. S., Akerley, W., Bepler, G., Blum, M. G., Chang, A., Cheney, R. T., Chirieac, L. R., D'Amico, T. A., Demmy, T. L., Ganti, A. K. P., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0056 · Cited by 730
Kelly, K., Chansky, K., Gaspar, L. E., Albain, K. S., Jett, J., Ung, Y. C., Lau, D. H. M., Crowley, J. J., & Gandara, D. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4824 · Cited by 573
Self-citation
Metadata
- Authors
- Albain, K. S., Crowley, J. J., Turrisi, A. T., Gandara, D. R., Farrar, W. B., Clark, J. I., Beasley, K. R., & Livingston, R. B.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-08-15
- Volume
- 20
- Issue
- 16
- Pages
- 3454-3460
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1986794774
- Cited by
- 343
- References
- 8
- FWCI
- 17.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.